Acute leukemias are rapidly progressing blood cancers characterized by the accumulation of immature white blood cells in the bone marrow and blood. They include acute myeloid leukemia and acute lymphoblastic leukemia subtypes, among others.
West Virginia University Cancer Institute has dosed the first patient in a phase 1/2 trial evaluating subcutaneous blinatumomab for CD19-positive mixed-phenotype acute leukemia, a rare disease with no FDA-approved therapies. The first patient achieved complete remission after one cycle.
A Phase II trial led by WVU Cancer Institute reports the first-ever use of subcutaneous blinatumomab in CD19-positive mixed phenotype acute leukemia, with the first patient achieving complete remission after one cycle.
Orca-T, an investigational T-cell therapy under FDA priority review, is being studied to reduce graft-versus-host disease in patients undergoing allogeneic stem cell transplant for acute leukemias and high-risk blood disorders, with a decision expected in April 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07295951 |
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia |
RECRUITING | PHASE1 |
| NCT05521087 |
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias |
WITHDRAWN | PHASE1 |
| NCT02145039 |
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases |
TERMINATED | NA |
| NCT02141828 |
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene |
COMPLETED | PHASE1 |
| NCT01919866 |
Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells |
UNKNOWN | PHASE1/PHASE2 |
| NCT01826214 |
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia |
COMPLETED | PHASE2 |
| NCT01479582 |
Providing Access to Cord Blood Units for Transplants |
WITHDRAWN | PHASE2 |
| NCT01339988 |
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) |
UNKNOWN | PHASE4 |
